Novavax to Present at the Ladenburg Thalmann 2015 Healthcare Conference

GAITHERSBURG, Md., Sept. 21, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that Stanley C. Erck, President and CEO, will present at the Ladenburg Thalmann Healthcare 2015 Conference.

Conference details are as follows:

Date: Tuesday, September 29, 2015Time: 1:30 – 1:55 p.m. US Eastern TimeLocation: Sofitel Hotel, New York CityLive webcast: http://wsw.com/webcast/ladenburg/nvax

The webcast and a replay of the presentation will also be accessible under the “Investors/Events” section of the Novavax website at novavax.com.

About Novavax

Novavax, Inc. (Nasdaq: NVAX) is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Our recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. Additional information about Novavax is available on the Company’s website, novavax.com.

Contact:
Novavax, Inc.

Barclay A. Phillips
SVP, Chief Financial Officer and Treasurer

Andrea N. Flynn, Ph.D.
Senior Manager, Investor Relations

[email protected]
240-268-2000

Russo Partners, LLC

David Schull
Todd Davenport, Ph.D.

[email protected]
[email protected]
212-845-4271  

You May Also Be Interested In

• Novavax's Nuvaxovid wins approval in U.S., EU, Japan for 2026-2027
• ASM share buyback update August 24 – 28, 2026
• adapfin to Build a Banking Product Live in Under Seven Minutes at Finovate Fall 2026